Drug intelligence / Profile preview

VM200

Development stage: Preclinical
Lead developer: Vision Medicines
Modality: Small Molecules
Administration: Oral

Overview

VM200 is an oral small molecule drug candidate developed by Vision Medicines, licensed from Case Western Reserve University. It is intended for the treatment of Stargardt disease, an orphan retinal disease that leads to legal blindness. The drug's mechanism of action involves trapping a toxic vitamin A byproduct, which in turn reduces retinal damage. Its development is supported by funding from the Foundation Fighting Blindness, aiming to advance it from preclinical stages through clinical proof-of-concept.

Targets

ATR (ATR serine/threonine kinase)

Beyond the preview

Go deeper on VM200.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VM200.

Explore the full profile